Latest information on COVID-19

The CDCM bridges the divide between laboratory discovery and translation to patients in clinical trials

What is CDCM?

The Center for Definitive and Curative Medicine (CDCM) is the translational arm of the Institute for Stem Cell Biology and Regenerative Medicine. The CDCM was established as a joint initiative of the Stanford University School of Medicine, Stanford Health Care and Stanford Children’s Health. It is co-directed by Drs. Maria Grazia Roncarolo, Anthony Oro, and Matthew Porteus.

The CDCM provides the know-how, organizational and physical infrastructure to support investigator-initiated clinical translational studies on cell and gene therapy (CGT) from initial discovery through completion of clinical proof-of-concept trials. Stanford Medicine’s clinical enterprise provides an exemplary clinical environment in which to deploy cures. The CDCM supports the development of life-changing and curative treatments for patients who come to Stanford to receive the highest level of care.

Watch our Video!

Why Stanford University?

A number of distinguishing features make Stanford particularly well-positioned to succeed

Pre-eminent, highly-funded cell and gene therapy program

Significant investment in translational infrastructure on campus

State-of-the-art GMP facility

Excellence in clinical care and access to patient populations

Why Cell and Gene Therapy?

NEWS: HIGHLIGHTS

Jasper Therapeutics Announces Treatment of First Patient in JSP191 Conditioning Study

May 17, 2022

The CDCM's collaboration with Jasper Therapeutics has resulted in the successful launch of an investigator-initiated clinical trial treating patients with Fanconi Anemia. Read the latest news here.


CDCM 6th Annual Symposium Recap

March 29, 2022

Every year, the Center for Definitive and Curative Medicine (CDCM) hosts a symposium gathering experts from gene and cell therapy fields to discuss their new discoveries, clinical development, and challenges in bringing treatments to patients with unmet needs. This year’s symposium “Delivering on Curative Promises” featured 10 distinguished speakers and drew 600+ registrants, cementing another successful event from the CDCM. We received an overwhelming amount of positive feedback from attendees, Stanford University leadership, industry partners, hospital leadership, and our sponsors for arranging a day that was educational, scientifically cutting edge, versatile, entertaining, and for most attendees, deeply meaningful.

This year’s keynote speakers were:

  •  Marina Cavazzana, MD, Director of Biotherapy Department - Hôpital Necker Enfants Malades - Paris – France
  • Irv Weissman, MD, Director, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University

 

We would like to thank all participants, speakers, and sponsors for their continued support of the CDCM, the goal of translating Stanford University discoveries to cures for patients with both rare and common diseases, and the development of a unique infrastructure to achieve this goal.

We look forward to the 7th annual symposia and hope you will be able to join us again.

 

The symposium is an annual conference put on by the CDCM (http://med.stanford.edu/cdcm.html). The Center provides the organizational and physical infrastructure to support investigator-initiated clinical translational studies in stem cell and gene therapy from initial discovery through completion of clinical proof-of-concept studies.


Rosa Bacchetta, MD Receives $12 Million in CIRM Funding for IPEX clinical trial

Oakland, February 24, 2022

The California Institute for Regenerative Medicine (CIRM) has invested approximately $12 million in a therapy being tested in a clinical trial to help patients that are affected by IPEX Syndrome. IPEX Syndrome is a rare autoimmune condition where an individual’s body cannot control their immune responses; this results in immune cells attacking their own healthy tissue. It is more commonly diagnosed in boys during the first year of life and is often fatal.

Dr. Rosa Bacchetta and her team have developed a therapy that utilizes a patient’s own CD4 T cells, which have been genetically modified to properly express the FOXP3 gene. Because the cells originate from the patient, there are less concerns regarding potential rejection and other fatal transplant complications. Dr. Bacchetta has received approval from the FDA to test this therapy in a Phase 1 clinical trial for affected patients (NCT05241444).

For more information, please contact Abinaya Nathan, Project Manager (abnathan@stanford.edu). The CIRM press release can be found here.


IND Clearance Received for Sickle Cell Disease Gene Editing Clinical Trial

December 14, 2020

FDA Investigational New Drug (IND) clearance has been received to launch a phase I/II clinical trial of gene correction for sickle cell disease. 

Learn More>>


California Votes Yes on Proposition 14: California Stem Cell Research, Treatments and Cures Initiative of 2020

November 13, 2020

California voters vote Yes on Prop 14! This proposition provides needed funding to continue investing in the research and discovery of stem cell treatments and cures for chronic illnesses and conditions.

Learn More>>


Dr. Porteus' article featured in a Nature Communications Editors’ Highlights webpage

May 18, 2020

The editors at Nature Communications have put together an Editors’ Highlights webpage of recent research on Therapeutics and have chosen to feature Dr. Porteus' article, entitled “Cas9-AAV6-Engineered Human Mesenchymal Stromal Cells Improved Cutaneous Wound Healing in Diabetic Mice”. 

Learn More>>